No products in the cart.
Pre-made Matuzumab benchmark antibody ( Whole mAb, anti-EGFR therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-337
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Matuzumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Matuzumab (formerly EMD 72000) is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. The mouse monoclonal antibody (mAb425) from which matuzumab was developed at the Wistar Institute in Philadelphia, Pennsylvania
| Products Name (INN Index) | Pre-Made Matuzumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody |
|---|---|
| INN Name | Matuzumab |
| Target | EGFR |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | nd |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 3c08:HL/5vr9:HL:AB |
| 99% SI Structure | 5vsi:HL/3c09:HL:CB |
| 95-98% SI Structure | None |
| Year Proposed | 2003 |
| Year Recommended | 2003 |
| Companies | ImClone Systems,Merck KGaA,Takeda |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Cervical cancer,Colorectal cancer,Gastric cancer,Head and neck cancer,Non-small cell lung cancer,Ovarian cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | EGFR |
| Package |
Previous slide
Next slide
